Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EPI-326

Phase 1Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Growth FactorRecruiting

Growth FactorPhase 1

Recruiting

Timeline

Expected Milestones

Q3 2029

Phase 1Recruiting

Growth Factor

NCT07462377

Clinical

Trials by Indication[1]

Growth Factor1 trial

A First-in-Human, Open-label, Multicenter, Phase 1 Study of EPI-326 in Patients With Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma

Recruiting·EEpiBiologics·Phase 1·NCT07462377·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EPI-326. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EPI-326 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EPI-326. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EpiBiologics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EEpiBiologics

Related News